Particle growth behavior of carbon-supported Pt, Ru, PtRu catalysts prepared by an impregnation reductive-pyrolysis method for direct methanol fuel cell anodes

ArticleJournal of Catalysis. 229(1):176-184 (2005)journal articl

Performance of ternary PtRuRh/C electrocatalyst with varying Pt : Ru : Rh ratio for methanol electro-oxidation

ArticleJournal of Applied Electrochemistryjournal articl

Kinetics of CH3OH oxidation on PtRu/C studied by impedance and CO stripping voltammetry

ArticleJournal of Electroanalytical Chemistry. 576(2):215-221 (2005)journal articl

Strict Limit on CPT Violation from Polarization of Gamma-Ray Bursts

We report the strictest observational verification of CPT invariance in the photon sector, as a result of gamma-ray polarization measurement of distant gamma-ray bursts (GRBs), which are brightest stellar-size explosions in the universe. We detected the gamma-ray polarization of three GRBs with high significance, and the source distances may be constrained by a well-known luminosity indicator for GRBs. For the Lorentz- and CPT-violating dispersion relation E_{\pm}^2=p^2 \pm 2\xi p^3/M_{Pl}, where \pm denotes different circular polarization states of the photon, the parameter \xi is constrained as |\xi|<O(10^{-15}). Barring precise cancellation between quantum gravity effects and dark energy effects, the stringent limit on the CPT-violating effect leads to the expectation that quantum gravity presumably respects the CPT invariance.Comment: 4 pages; accepted for publication in Physical Review Letters; redshift estimates of GRBs changed (i.e z=0.382 was wrong for GRB 110721A) and calculations of \xi limit improved from the previous versio

High-efficacy targeting of colon-cancer liver metastasis with Salmonella typhimurium A1-R via intra-portal-vein injection in orthotopic nude-mouse models.

Liver metastasis is the main cause of colon cancer-related death and is a recalcitrant disease. We report here the efficacy and safety of intra-portal-vein (iPV) targeting of Salmonella typhimurium A1-R on colon cancer liver metastasis in a nude-mouse orthotopic model. Nude mice with HT29 human colon cancer cells, expressing red fluorescent protein (RFP) (HT29-RFP), growing in the liver were administered S. typhimurium A1-R by either iPV (1×104 colony forming units (CFU)/100 μl) or, for comparison, intra-venous injection (iv; 5×107 CFU/100 μl). Similar amounts of bacteria were delivered to the liver with the two doses, indicating that iPV delivery is 5×103 times more efficient than iv delivery. Treatment efficacy was evaluated by tumor fluorescent area (mm2) and total fluorescence intensity. Tumor fluorescent area and fluorescence intensity highly correlated (p&lt;0.0001). iPV treatment was more effective compared to both untreated control and iv treatment (p&lt;0.01 and p&lt;0.05, respectively with iPV treatment with S. typhimurium arresting metastatic growth). There were no significant differences in body weight between all groups. The results of this study suggest that S. typhimurium A1-R administered iPV has potential for peri-operative adjuvant treatment of colon cancer liver metastasis

MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX).

A pancreatic ductal adenocarcinoma (PDAC), obtained from a patient, was grown orthotopically in the pancreatic tail of nude mice to establish a patient-derived orthotopic (PDOX) model. Seven weeks after implantation, PDOX nude mice were divided into the following groups: untreated control (n = 7); gemcitabine (100 mg/kg, i.p., once a week for 2 weeks, n = 7); cobimetinib (5 mg/kg, p.o., 14 consecutive days, n = 7); trametinib (0.3 mg/kg, p.o., 14 consecutive days, n = 7); trabectedin (0.15 mg/kg, i.v., once a week for 2 weeks, n = 7); temozolomide (25 mg/kg, p.o., 14 consecutive days, n = 7); carfilzomib (2 mg/kg, i.v., twice a week for 2 weeks, n = 7); bortezomib (1 mg/kg, i.v., twice a week for 2 weeks, n = 7); MK-1775 (20 mg/kg, p.o., 14 consecutive days, n = 7); BEZ-235 (45 mg/kg, p.o., 14 consecutive days, n = 7); vorinostat (50 mg/kg, i.p., 14 consecutive days, n = 7). Only the MEK inhibitors, cobimetinib and trametinib, regressed tumor growth, and they were more significantly effective than other therapies (p &lt; 0.0001, respectively), thereby demonstrating the precision of the PDOX models of PDAC and its potential for individualizing pancreatic-cancer therapy

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.

Melanoma is a recalcitrant disease. The present study used a patient-derived orthotopic xenograft (PDOX) model of melanoma to test sensitivity to three molecularly-targeted drugs and one standard chemotherapeutic. A BRAF-V600E-mutant melanoma obtained from the right chest wall of a patient was grown orthotopically in the right chest wall of nude mice to establish a PDOX model. Two weeks after implantation, 50 PDOX nude mice were divided into 5 groups: G1, control without treatment; G2, vemurafenib (VEM) (30 mg/kg); G3; temozolomide (TEM) (25 mg/kg); G4, trametinib (TRA) (0.3 mg/kg); and G5, cobimetinib (COB) (5 mg/kg). Each drug was administered orally, daily for 14 consecutive days. Tumor sizes were measured with calipers twice a week. On day 14 from initiation of treatment, TRA, an MEK inhibitor, was the only agent of the 4 tested that caused tumor regression (P &lt; 0.001 at day 14). In contrast, another MEK inhibitor, COB, could slow but not arrest growth or cause regression of the melanoma. First-line therapy TEM could slow but not arrest tumor growth or cause regression. The patient in this study had a BRAF-V600E-mutant melanoma and would be considered to be a strong candidate for VEM as first-line therapy, since VEM targets this mutation. However, VEM was not effective. The PDOX model thus helped identify the very-high efficacy of TRA against the melanoma PDOX and is a promising drug for this patient. These results demonstrate the powerful precision of the PDOX model for cancer therapy, not achievable by genomic analysis alone

A variability study of the Seyfert 2 galaxy NGC 6300 with XMM-Newton

We present the results of timing analysis of the XMM-Newton observation of the Seyfert 2 galaxy NGC 6300. The hard X-ray spectrum above 2 keV consists of a Compton-thin-absorbed power law, as is often seen in Seyfert 2 galaxies. We clearly detected rapid time variability on a time scale of about 1000 s from the light curve above 2 keV. The excess variance of the time variability (sigma2_RMS) is calculated to be ~0.12, and the periodogram of the light curve is well represented by a power law function with a slope of 1.75. In contrast with previous results from Seyfert 2 nuclei, these variability characteristics are consistent with those of Seyfert 1 galaxies. This consistency suggests that NGC 6300 has a similar black hole mass and accretion properties as Seyfert 1 galaxies. Using the relation between time variability and central black hole mass by Hayashida et al. (1998), the black hole mass of NGC 6300 is estimated to be ~2.8x10^5 Mo. Taking uncertainty of this method into account, the black hole mass is less than 10^7 Mo. Taking the bolometric luminosity of 3.3x10^43 erg/s into consideration, this yields an accretion rate of > 0.03 of the Eddington value, and comparable with estimates from Seyfert 1 galaxies using this method. The time variability analysis suggests that NGC 6300 actually has a Seyfert 1 nucleus obscured by a thick matter, and more generally provides a new pillar of support for the unified model of Seyfert galaxies based on obscuration.Comment: 11 pages, 6 figures, accepted for publication in Ap